Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamar Amit

Showing results (21-30 of 88) with videos related to

Pageof 9
Sort By:
Parkinsonism & Related Disorders|November 23, 2013
Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's diseaseMoussa B H Youdim, Lana Kupershmidt, Tamar Amit, et al.
Progress in Neurobiology|July 6, 2010
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activityOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
Journal of Molecular Neuroscience : MN|May 14, 2016
Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1(G93A) Transgenic ALS MiceSagit Golko-Perez, Tamar Amit, Moussa B H Youdim, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 9, 2005
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamineOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
Journal of Neurochemistry|December 17, 2009
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagilineOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
Progress in Neurobiology|July 31, 2007
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agentsSilvia Mandel, Tamar Amit, Orit Bar-Am, et al.
Journal of Molecular Neuroscience : MN|August 30, 2008
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged ratsOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
Annals of the New York Academy of Sciences|December 14, 2007
Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapyOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 1, 2007
Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelatorsTamar Amit, Yael Avramovich-Tirosh, Moussa B H Youdim, et al.
Current Drug Targets|January 28, 2012
Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatmentOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
Pageof 9

Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Parkinsonism & Related Disorders|November 23, 2013
Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's diseaseMoussa B H Youdim, Lana Kupershmidt, Tamar Amit, et al.
Progress in Neurobiology|July 6, 2010
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activityOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
Journal of Molecular Neuroscience : MN|May 14, 2016
Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1(G93A) Transgenic ALS MiceSagit Golko-Perez, Tamar Amit, Moussa B H Youdim, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 9, 2005
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamineOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
Journal of Neurochemistry|December 17, 2009
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagilineOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
Progress in Neurobiology|July 31, 2007
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agentsSilvia Mandel, Tamar Amit, Orit Bar-Am, et al.
Journal of Molecular Neuroscience : MN|August 30, 2008
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged ratsOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
Annals of the New York Academy of Sciences|December 14, 2007
Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapyOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 1, 2007
Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelatorsTamar Amit, Yael Avramovich-Tirosh, Moussa B H Youdim, et al.
Current Drug Targets|January 28, 2012
Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatmentOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
Pageof 9